Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801175 | 0.85 | ALDH1A1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL6801149 | 0.85 | MEN1 (0.52) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL6800958 | 0.82 | GAA (0.53) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL8510557 | 0.76 | GPR119 (0.67) | MEN1KMT2AGPR119TGFBR1STS | |
| SCHEMBL19450297 | 0.75 | MMP2 (0.56) | MEN1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL6799380 | 0.75 | ALDH1A1 (0.56) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL5090951 | 0.75 | CA1 (0.57) | SMN1; SMN2GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL28588397 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL8346439 | 0.74 | MEN1 (0.50) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL14473426 | 0.74 | ALDH1A1 (0.48) | MEN1KMT2AGPR119SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | MEN1 2627/4885KMT2A 1041/4885GPR119 4/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | MEN1 2724/4885KMT2A 906/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.